10x1000 Launches “Flex” Fintech Program with Partners Worldwide to Bridge Global Digital Skills Gap and Drive Financial Inclusion
16.9.2021 05:27:00 EEST | Business Wire | Press release
Fintech training platform 10x1000 Tech for Inclusion announced that it will deepen its collaborations with partners worldwide, working with leading global organizations, tech investors, and industry organizations to offer a program that enables aspiring practitioners to learn from global experts at their own pace.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915006200/en/
(Graphic: Business Wire)
Available from October through grants to over 1,000 learners, the Fintech Foundation Program Flex is a fully online certificate program providing practitioners with the mindset, knowledge and skills to become drivers of digital economic growth, according to 10x1000, a global and philanthropic fintech training initiative launched jointly by the International Finance Corporation (IFC), a member of the World Bank Group, and Alipay in 2018.
Flex learners will be recruited through partners such as the IFC (including the SME Finance Forum), United Nations Economic Commission for Africa, Dubai International Financial Centre, Malaysia Digital Economy Corporation, KPMG and fintech associations from Hong Kong, Malaysia, the Philippines, Thailand, and Singapore. (See table for a full list of 10X1000 partners)
“We are delighted to join hands with global partners to bring the 10x1000 training platform to learners worldwide, as we seek innovative approaches to meeting a common goal of bridging the digital skills gap, particularly in communities that need it the most,” said Eric Jing, Chairman and CEO of Ant Group, owner and operator of digital payments platform Alipay. “I am excited that learners from 10x1000’s new Flex program will gain the fintech knowledge they need to support their communities, and help bring us closer to meeting the UN Sustainable Development Goals (SDGs).”
“IFC has been a steadfast supporter of digital innovations that foster financial inclusion. As nations emerge from the Covid-19 pandemic, the world is in need of more visionary fintech leaders to drive such innovation and expand financial access,” said Qamar Saleem, Regional Manager for Advisory Services, Financial Institutions Group, Asia and Pacific, IFC. “We believe 10x1000’s Flex program will bring distinct value to complement existing educational resources with a flexible curriculum that draws on practical experience of leading fintech practitioners across regions.”
Through eight recorded video lectures, attendees of the new Flex program will hear directly from tech entrepreneurs, senior leaders at Ant and other fintech firms as well as distinguished scholars, sharing their first-hand knowledge on topics ranging from ‘the tech behind fintech’ and best practices in leveraging technology to solve real business problems.
Training content provided by 10x1000 is being guided by a Curriculum Steering Committee (CSC), an advisory body responsible for ensuring the quality and effectiveness of the curriculum. The current committee is composed of global experts from industry, academia, and international financial institutions.
Going forward, 10x1000 will also work with partners and alumni to cultivate a global fintech community, creating a vibrant platform that provides opportunities for willing organizations and individuals to contribute to global financial inclusion.
About 10x1000
10x1000 Tech for Inclusion is an open and global fintech training platform that enables learners to become drivers of digital economic growth. Its mission is to train 1,000 emerging talents and tech leaders each year for the next ten years. 10x1000 is a philanthropic initiative launched jointly by the International Finance Corporation (IFC), a member of the World Bank Group, and Alipay in 2018.
** 10x1000 Tech for Inclusion Partners List **
Founding Partners
1. Alipay (Alipay)
2. IFC (International Finance Corporation)
Global Organizations
1. UNECA (United Nations Economic Commission for Africa)
2. UNWFP (United Nations World Food Programme)
3. SME Finance Forum (SME Finance Forum, Managed by the IFC)
Regional-Country Industry Organizations
1. Africa’s Business Heroes (ABH)
2. DIFC (Dubai International Financial Centre)
3. FTAHK (FinTech Association of Hong Kong)
4. FAOM (FinTech Association of Malaysia)
5. Fintech Alliance PH Inc (Fintech Alliance.ph)
6. MDEC (Malaysia Digital Economy Corporation)
7. MFTA (MENA Fintech Association)
8. SFA (Singapore FinTech Association)
9. SLT (She Loves Tech)
10. TFA (Thai Fintech Association)
Professional Services/Investors
1. BAce Capital (BAce Capital)
2. Gobi Partners (Gobi Partners)
3. KPMG (KPMG)
4. 917Ventures (917Ventures)
** 10x1000 Curriculum Steering Committee Members (2021) **
Nafez Dakkak
Executive Chairman, Edraak.org
Pooma Kimis
Director, Bernstein Autonomous
Qamar Saleem
Regional Industry Manager Asia & Pacific, Financial Institutions Group at International Finance Corporation (IFC)
Daniel Suen
Head of Strategy, International Education, General Manager, China Education, Wiley
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915006200/en/
Contact information
Media
Daryl Loo, Alipay
looliatliang.dlll@alipay.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom